SI
RARE icon

Sofinnova Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sofinnova Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
500,000
+150,000
+43% +$3.73M 0.86% 30
2026
Q1 		$7.33M Buy
+350,000
New +$7.88M 0.28% 52

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Sofinnova Investments's RARE Position: Q2 2026 in Review

Sofinnova Investments reduced its Ultragenyx Pharmaceutical (RARE) stake by 45% in Q2 2026, selling an estimated $35.5M and leaving 1,717,505 shares worth $57.3M. The position accounts for 2.96% of the portfolio, ranked #8.

Sofinnova Investments first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. The position peaked at $65.9M in Q1 2026. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Sofinnova Investments held 1,717,505 shares of Ultragenyx Pharmaceutical worth $57.3M as of Q2 2026.
  • Sofinnova Investments sold 1,428,383 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $35.5M.
  • Ultragenyx Pharmaceutical made up 2.96% of Sofinnova Investments's portfolio in Q2 2026, its #8 holding.
  • Sofinnova Investments first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Sofinnova Investments's Ultragenyx Pharmaceutical position peaked at $65.9M in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.